- Home
- NUW vs PROK Comparison
NUW vs PROK Comparison
Compare NUW & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- PROK
- Stock Information
- Founded
- NUW 2008
- PROK 2015
- Country
- NUW United States
- PROK United States
- Employees
- NUW N/A
- PROK N/A
- Industry
- NUW Investment Managers
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NUW Finance
- PROK Health Care
- Exchange
- NUW Nasdaq
- PROK Nasdaq
- Market Cap
- NUW 246.1M
- PROK 220.6M
- IPO Year
- NUW N/A
- PROK N/A
- Fundamental
- Price
- NUW $13.84
- PROK $1.69
- Analyst Decision
- NUW
- PROK Buy
- Analyst Count
- NUW 0
- PROK 5
- Target Price
- NUW N/A
- PROK $4.50
- AVG Volume (30 Days)
- NUW 45.3K
- PROK 438.7K
- Earning Date
- NUW 01-01-0001
- PROK 11-12-2024
- Dividend Yield
- NUW 3.66%
- PROK N/A
- EPS Growth
- NUW N/A
- PROK N/A
- EPS
- NUW N/A
- PROK N/A
- Revenue
- NUW N/A
- PROK N/A
- Revenue This Year
- NUW N/A
- PROK N/A
- Revenue Next Year
- NUW N/A
- PROK N/A
- P/E Ratio
- NUW N/A
- PROK N/A
- Revenue Growth
- NUW N/A
- PROK N/A
- 52 Week Low
- NUW $12.45
- PROK $1.18
- 52 Week High
- NUW $14.44
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- NUW 44.03
- PROK 45.01
- Support Level
- NUW $13.71
- PROK $1.50
- Resistance Level
- NUW $13.89
- PROK $1.81
- Average True Range (ATR)
- NUW 0.15
- PROK 0.20
- MACD
- NUW 0.00
- PROK -0.02
- Stochastic Oscillator
- NUW 23.58
- PROK 24.84
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.